The largest database of trusted experimental protocols

Vironostika hiv 1 microelisa

Manufactured by bioMérieux

The Vironostika HIV-1 MicroElisa is a laboratory diagnostic instrument used for the detection of antibodies to the human immunodeficiency virus type 1 (HIV-1) in human serum or plasma samples. The core function of this product is to perform enzyme-linked immunosorbent assay (ELISA) testing to identify the presence of HIV-1 antibodies.

Automatically generated - may contain errors

Lab products found in correlation

2 protocols using vironostika hiv 1 microelisa

1

HIV-1 Near Full-Length Genomes in Brazil

Check if the same lab product or an alternative is used in the 5 most similar protocols
The MPS data used in the present study were derived from 134 HIV-1 near full-length genomes (NFLG) with predetermined subtype by Illumina ultra-deep sequencing technology [33 (link)]. These samples were sourced from four Brazilian states (41 from São Paulo [SP], 31 from Minas Gerais [MG], 77 from Pernambuco [PE], and 53 from Rio de Janeiro [RJ]) and were previously classified by less-sensitive (LS) or “detuned” enzyme immunoassay (Vironostika HIV-1 MicroElisa; bioMérieux, Durham, NC) or an LS chemiluminescent immunoassay (Vitros HIV-1/2 Assay; Ortho Diagnostics, Rochester, NY) as non-recent or longstanding infections being Recent Infection Testing Algorithm (RITA) reactive [22 (link)]. None of the participants had been exposed to any ARV at the time of sampling (i.e. treatment-naïve). The sequences used in this study are publicly available through the Zenodo repository browser [33 (link), 34 ]; therefore, no institutional review board (IRB) approval is required.
+ Open protocol
+ Expand
2

Genetic Diversity of Recently Infected HIV-1

Check if the same lab product or an alternative is used in the 5 most similar protocols
Previously, we had described the genetic diversity of HIV-1 using partial (n = 6) and near full-length genomes (NFLG) sequence (n = 39) of human immunodeficiency virus Type 1 provirus deep sequencing data from recently infected donors at four blood centers participating in the Retrovirus Epidemiology Donor Study (REDS-II) International Program in Brazil [23 ]. Samples were classified by less-sensitive (LS) or “detuned” enzyme immunoassay (Vironostika HIV-1 MicroElisa; bioMérieux, Durham, NC) or an LS chemiluminescent immunoassay (Vitros HIV-1/2 Assay; Ortho Diagnostics, Rochester, NY) as recently infected at the time of donation based on antibody levels consistent with recent seroconversion (infected for <170 days) as previously described [24 (link)]. None of the participants received antiviral treatment before. All study subjects provided written informed consent. The study was approved by the local ethical review committee of participating institutions as well as the REDS-II collaborating centers (Blood Systems Research Institute/University of California at San Francisco, San Francisco, CA) and data coordinating center (Westat, Inc.) in the United States.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!